First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Public ClinicalTrials.gov record NCT05759949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Therapies in Participants With Advanced Breast Cancer and as a Single Agent in Advanced Solid Tumors
Study identification
- NCT ID
- NCT05759949
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Relay Therapeutics, Inc.
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Interventions
- Abemaciclib Drug
- Fulvestrant Drug
- Palbociclib Drug
- RLY-5836 Drug
- Ribociclib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2023
- Primary completion
- Mar 17, 2025
- Completion
- Apr 10, 2025
- Last update posted
- May 15, 2025
2023 – 2025
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | — |
| Community Cancer Center North | Indianapolis | Indiana | 46250 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Memorial Sloan Kettering Cancer Center-Main Campus | New York | New York | 10065 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05759949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 15, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05759949 live on ClinicalTrials.gov.